REGENXBIO Inc. (RGNX) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 40 days, typically, give or take 14 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 5, 2026before open 36 8-K
Q2 FY2026Thu, Aug 6, 2026before open 37 8-K
Q1 FY2026Thu, May 14, 2026before open 44 8-K
Q4 FY2025Thu, Mar 5, 2026before open 64 8-K
Q3 FY2025Thu, Nov 6, 2025before open 37 8-K
Q2 FY2025Thu, Aug 7, 2025before open 38 8-K
Q1 FY2025Mon, May 12, 2025after close 42 8-K
Q4 FY2024Thu, Mar 13, 2025after close 72 8-K

What they guided beta

Q3 FY2026 "Topline data from pivotal subretinal wet AMD studies, ATMOSPHERE ® and ASCENT ® , expected in Q4 2026" exhibit
Q3 FY2026 "The Company expects to have a pre-Biologics License Application (BLA) meeting with the FDA in Q4 2026 and is on track to submit a BLA in Q1 2027 under the accelerated approval pathway, supporting potential approval in 2H 2027." exhibit
Q3 FY2026 "REGENXBIO expects to initiate AFFINITY ® RISE, an ex-U.S. randomized, placebo-controlled study to support RGX-202 global regulatory submissions, in 1H 2027." exhibit
Q3 FY2026 "REGENXBIO expects to announce topline data with AbbVie from the ATMOSPHERE ® and ASCENT ® pivotal trials of sura-vec using subretinal delivery in Q4 2026." exhibit
Q3 FY2026 "Global regulatory submissions are expected in 2027." exhibit
Q2 FY2026 "Long-term surabgene lomparvovec (sura-vec, ABBV-RGX-314) data highlight durable safety and efficacy profile ahead of key catalyst o Topline data from pivotal subretinal wet AMD studies, ATMOSPHERE ® and ASCENT ® , expected in Q4 2026 o Phase IIb/III NAAVIGATE trial for diabetic retinopathy ongoing" exhibit
Q2 FY2026 "Reaffirmed path forward for RGX-121 for Hunter syndrome with FDA during productive July Type A meeting; resubmission on track for Q3 2026" exhibit
Q2 FY2026 "“Our second quarter was defined by strong clinical execution across our pipeline: the Phase III AFFINITY DUCHENNE ® trial met its primary endpoint, we dosed the first participant in the NAAVIGATE study in diabetic retinopathy, and the FDA reaffirmed the path forward for RGX-121,” said Curran Simpson, President and Chief Executive Officer of REGENXBIO." exhibit
Q2 FY2026 "In addition to extending the company’s expected cash runway into Q4 2027, proceeds will support the initiation of the planned AFFINITY ® RISE ex-U.S. randomized-controlled trial in 1H 2027 to support global regulatory submissions for RGX-202." exhibit
Q2 FY2026 "REGENXBIO expects to initiate AFFINITY ® RISE, a new, ex-U.S. randomized, placebo-controlled study to support RGX-202 global regulatory submissions, in 1H 2027." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/RGNX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/RGNX

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

RGNX earnings date badge

HTML

<a href="https://veritasdata.dev/company/RGNX/"><img src="https://veritasdata.dev/embed/RGNX.svg" alt="RGNX earnings date" width="240" height="56"></a>

Markdown

[![RGNX earnings date](https://veritasdata.dev/embed/RGNX.svg)](https://veritasdata.dev/company/RGNX/)

Script

<script async src="https://veritasdata.dev/embed/RGNX.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/RGNX"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.